MISSISSAUGA, ON, March 6, 2015 /CNW/ - Covalon Technologies Ltd, (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced the introduction of its new MediClear™ product line designed to significantly improve patient compliance with efforts to reduce surgical site infections (SSI).
Included in the MediClear™ line is Covalon's patent-pending MediClear™ PreOp – Antimicrobial Silicone Film Dressing, designed to replace other pre-operative skin preparation products, Covalon's next generation antimicrobial MediClear™ PostOp dressing and MediClear™ Scar. All three will be presented at AORN (Association of Perioperative Registered Nurses) Surgical Conference & Expo.
"MediClear™ PreOp, PostOp and Scar will meet the growing demand for infection management and post-operative scar reduction products, and are the latest examples of Covalon's innovation in antimicrobial silicone adhesive technologies" said John R. Hands, Senior Director of Marketing at Covalon.
Preoperative skin preparation products are a critical part of an infection control bundle, aimed at reducing surgical site infections (SSIs). A 2014 study suggested SSIs account for in excess of $3.5 billion in healthcare expenditures per year in the United States1, not including the additional costs of hospitalization, post-discharge outpatient expenses, and long-term disability care and management2. Covalon's MediClear™ line is intended to help reduce this financial burden on the U.S. healthcare system.
MediClear™ PreOp – Silicone Film Dressing for PreOperative Skin Preparation with Chlorhexidine and Silver provides perioperative professionals with a patent-pending solution to patient non-compliance that exists with current chlorhexidine soap and wipe modalities.
"A product only works if a patient uses it, and we know that complicated instructions are a factor in patient non-compliance for traditional skin preparations" said Hands. "MediClear PreOp's application and comfort removes compliance as an issue, while also delivering continuous bactericidal and re-growth suppression for up to 7 days before the patient's surgery."
The AORN Surgical Conference & Expo is the largest surgical tradeshow in the U.S., reaching over 5,000 prospective clients and partners in Denver, from March 8-10th. Visit Covalon at their booth #3742 during exhibit hours which can be found at www.aorn.org/surgicalexpo/
1 Anderson DJ, Podgorny K, Berrios-Torres SI, et al. "Strategies to Prevent Surgical Site Infections in Acute Care Hospitals: 2014 Update." Infection Control and Hospital Epidemiology 35.6(2014): 605-627.
2 Magill SS, Edwards JR, Bamberg W, et al. "Multistate Point-Prevalence Survey of Health Care Associated Infections." New England Journal of Medicine 370(2014): 1198-1208.
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
SOURCE Covalon Technologies Ltd.
For further information: To learn more about Covalon, please contact: Brian Pedlar, CEO, Covalon Technologies Ltd., Email: firstname.lastname@example.org, Phone: 905.568.8400 x 233, Toll free: 1.877.711.6055, Web site: www.covalon.com, Twitter: @covalon